TICKERNOMICS Sign up
Last Update: 2024-12-27 15:21:45
AGILENT TECHNOLOGIES INC. ( A ) https://www.agilent.com
135.97USD
Sector:
Healthcare
Industry:
Diagnostics & Research
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-2.14%
A
SPY
32.66%
-12.78%
A
SPY
108.59%
A
66.69%
SPY
302.52%
A
278.15%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
39182.75
37997.41
0.56
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
30.40
6.02
6.64
3.61
0.70
21.54
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
23.99
100.00
26.92
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
8.2576
12.81
16.25
1.07
Other Earnings and Cash Flow Stats:
AGILENT TECHNOLOGIES INC. ( A ) Net Income TTM ($MM) is 1289.00
AGILENT TECHNOLOGIES INC. ( A ) Operating Income TTM ($MM) is 1488.00
AGILENT TECHNOLOGIES INC. ( A ) Owners' Earnings Annual ($MM) is 0.00
AGILENT TECHNOLOGIES INC. ( A ) Current Price to Owners' Earnings ratio is 0.00
AGILENT TECHNOLOGIES INC. ( A ) EBITDA TTM ($MM) is 1739.00
AGILENT TECHNOLOGIES INC. ( A ) EBITDA Margin is 26.92%
Capital Allocation:
AGILENT TECHNOLOGIES INC. ( A ) has paid 0.94 dividends per share and bought back 5.0 million shares in the past 12 months
AGILENT TECHNOLOGIES INC. ( A ) has reduced its debt by 2597.0 million USD in the last 12 months
Capital Structure:
AGILENT TECHNOLOGIES INC. ( A ) Interest-bearing Debt ($MM) as of last quarter is 184
AGILENT TECHNOLOGIES INC. ( A ) Annual Working Capital Investments ($MM) are 74
AGILENT TECHNOLOGIES INC. ( A ) Book Value ($MM) as of last quarter is 5898
AGILENT TECHNOLOGIES INC. ( A ) Debt/Capital as of last quarter is 3%
Other Balance Sheet Stats:
AGILENT TECHNOLOGIES INC. ( A ) has 1329 million in cash on hand as of last quarter
AGILENT TECHNOLOGIES INC. ( A ) has 1895 million of liabilities due within 12 months, and long term debt 2932 as of last quarter
AGILENT TECHNOLOGIES INC. ( A ) has 291 common shares outstanding as of last quarter
AGILENT TECHNOLOGIES INC. ( A ) has 0 million USD of preferred stock value
Academic Scores:
AGILENT TECHNOLOGIES INC. ( A ) Altman Z-Score is 5.22 as of last quarter
AGILENT TECHNOLOGIES INC. ( A ) Piotroski Score is 6.00 as of last quarter
Corporate Governance:
AGILENT TECHNOLOGIES INC. ( A ) largest shareholder is Retirement Systems of Alabama owning 63237 shares at 8.60 ($MM) value
MCDONNELL PADRAIG(an insider) Sold 47 shares of AGILENT TECHNOLOGIES INC. ( A ) for the amount of $7050.00 on 2024-09-27
0.28% of AGILENT TECHNOLOGIES INC. ( A ) is held by insiders, and 91.26% is held by institutions
AGILENT TECHNOLOGIES INC. ( A ) went public on 1999-11-18
Other AGILENT TECHNOLOGIES INC. ( A ) financial metrics:
FCF:1417.00
Unlevered Free Cash Flow:0.00
EPS:4.82
Operating Margin:23.99
Gross Profit Margin:100.00
Div. Payout Ratio%:21.31
Div. Growth YoY%:-14.95
Equity Return%:23.80
Beta:1.07
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About AGILENT TECHNOLOGIES INC. ( A ) :
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquar
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.